Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Growth 2024-2030

Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Growth 2024-2030

According to our LPI (LP Information) latest study, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size was valued at US$ million in 2023. With growing demand in downstream market, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.

The research report highlights the growth potential of the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.

As for March 26, 2020



1.BCG Vaccine Clinical Experiment for Against Covid-19

Researchers in four countries (the Netherlands, Australia, Germany, and the United Kingdom) will soon begin clinical trials of new coronaviruses using unconventional methods.They will test whether a century-old anti-tuberculosis (TB) vaccine (BCG) can broadly improve the body's immune system, making it better able to fight sars-cov-2 and possibly prevent infection altogether.The study will be administered to people at high risk, including physicians and nurses, and to older adults.

Researchers in Germany are also testing VPM1002, a genetically modified version of BCG, developed by the Max Planck Institute, in a Phase 3 trial.

The partners involved, Vakzine Project Management (VPM) and the Serum Institute of India, have already held promising discussions with the authorities regarding the implementation of a Phase III study with VPM1002 in Germany in order to investigate the effectiveness of the vaccine in elderly people and healthcare workers. "These population groups are particularly affected by the current pandemic", says Leander Grode, Managing Director of VPM "and could therefore particularly benefit from a vaccination with VPM1002". If the results are positive, VPM1002 could help ease the burden on healthcare systems until a vaccine specifically effective against SARS-CoV-2 becomes available.



2.Introduce of VPM1002，a Genetically Modified More Effective BCG Vaccine

VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. The BCG vaccine consists of an attenuated (weakened) version of a relative of Mycobacterium tuberculosis, the causative agent of TB. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract.

The vaccine candidate, originally developed at the Max Planck Institute for Infection Biology in Berlin by the group of Stefan H.E. Kaufmann, thus provides more effective protection against tuberculosis than the old vaccine and is intended for use in new-borns as well as for boosting a vaccination in adults.

Recent studies have shown that VPM1002 can also be effective against cancer and prevent the recurrence of bladder tumours.



3.Research Progress for VPM1002

Scientists have investigated this further development of the BCG vaccine in a series of studies in mice as well as in several clinical trials. In 2018, a Phase II study confirmed that VPM1002 is well tolerated by new borns and is effective.

The vaccine is currently being tested in a further Phase III study on adult volunteers in India.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Key Features:

The report on VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It may include historical data, market segmentation by Type (e.g., 0.5ml Package, 1ml Package), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. This include advancements in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 technology, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 new entrants, VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 new investment, and other innovations that are shaping the future of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. It includes factors influencing customer ' purchasing decisions, preferences for VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market.

Market Segmentation:

VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination

Segmentation by application
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Vakzine Projekt Management (VPM)
Serum Institute of India

Key Questions Addressed in this Report

What is the 10-year outlook for the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market?

What factors are driving VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market opportunities vary by end market size?

How does VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.